Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC By Ogkologos - June 30, 2026 130 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HARMONi-6 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage... June 17, 2026 Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities October 22, 2021 FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle... February 21, 2025 Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously... July 25, 2023 Load more HOT NEWS How to Spend Time with Friends and Family Now that COVID... FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic... Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell... Trial Should Change Care for AIDS-Related Kaposi Sarcoma in Sub-Saharan Africa
